{"id":391494,"date":"2014-11-25T00:00:00","date_gmt":"2014-11-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trtrid0414-biopharma-treatmenttrends-hepatitis-c-treatment-algorithms-claims-data-analysis-us-2014\/"},"modified":"2026-03-31T09:04:22","modified_gmt":"2026-03-31T09:04:22","slug":"trtrid0414-biopharma-treatmenttrends-hepatitis-c-treatment-algorithms-claims-data-analysis-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trtrid0414-biopharma-treatmenttrends-hepatitis-c-treatment-algorithms-claims-data-analysis-us-2014\/","title":{"rendered":"TreatmentTrends: Hepatitis C | Treatment Algorithms | Claims Data Analysis |  US | 2014"},"content":{"rendered":"<p>Hepatitis C virus (HCV) chronic infection is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The FDA\u2019s approval of Gilead\u2019s Sovaldi (sofosbuvir) and Johnson &#038; Johnson\/Janssen\/Medivir\u2019s Olysio (simeprevir) in 2013 ushered in an era of interferon-free therapy for chronic HCV infection and triggered a major shift in the HCV treatment paradigm. With the availability of these new agents and the anticipated near-term launch of other promising therapies (e.g., Gilead\u2019s Harvoni [sofosbuvir\/ledipasvir fixed-dose combination]), the treatment landscape for HCV is expected to rapidly evolve and experience major improvements in drug safety and tolerability, efficacy, compliance, and treatment duration. This report focuses on the current and anticipated use of Sovaldi- and Olysio-containing regimens, interferon-based regimens, and emerging interferon-free regimens\u2014including Gilead\u2019s Harvoni, Bristol-Myers Squibb\u2019s Daklinza (daclatasvir), and AbbVie\u2019s three-direct-acting agent (DAA) combination (ombitasvir\/paritaprevir\/ritonavir + dasabuvir)\u2014by capturing patient-share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior. We also evaluate physician-perceived strengths and weaknesses, barriers to uptake, and salesforce performance associated with key brands and physician awareness of, interest in, and potential impact of agents in development.<\/p>\n","protected":false},"template":"","class_list":["post-391494","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391494\/revisions"}],"predecessor-version":[{"id":576987,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391494\/revisions\/576987"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}